Residual Atherogenic Dyslipidemia in Normal-Weight Adults: The Role of Visceral Adiposity and Metabolic Dysfunction.
- 1ADEMA-University School, University of the Balearic Islands, 07009 Palma, Spain.
- 2Faculty of Medicine, University of Castilla La Mancha (UCLM), 02008 Albacete, Spain.
- 3Balearic Islands Health Service, 07010 Palma, Spain.
Abstract
Background. Body mass index (BMI) remains the most widely used tool for obesity classification and cardiometabolic risk stratification. However, increasing evidence suggests that normal BMI does not necessarily reflect metabolic health, particularly in individuals with hidden visceral adiposity and residual atherogenic dyslipidemia. The present study aimed to evaluate the prevalence of residual atherogenic dyslipidemia among normal-weight adults and to analyze its association with visceral adiposity, metabolic dysfunction, and lifestyle-related factors. Methods. A cross-sectional observational study was conducted in 166,008 Spanish workers aged 18-69 years with normal BMI (18.5-24.9 kg/m²) who underwent standardized occupational health examinations between 2022 and 2024. Anthropometric, biochemical, vascular, and lifestyle-related variables were evaluated. Visceral adiposity was estimated using waist-to-height ratio (WtHR) and the Metabolic Score for Visceral Fat (METS-VF). Residual atherogenic dyslipidemia was primarily assessed using the triglyceride-to-HDL cholesterol ratio (TG/HDL-c). Multivariable logistic regression analyses were performed to identify independent associations with elevated TG/HDL-c. Results. Despite normal BMI values, 8.0% of participants presented with an elevated TG/HDL-c ratio, 11.8% had central adiposity, 11.4% showed low HDL cholesterol, and 17.9% exhibited elevated blood pressure. Individuals with an elevated TG/HDL-c ratio demonstrated significantly higher waist circumference, WtHR, METS-VF, triglycerides, non-HDL cholesterol, fasting glucose, blood pressure, and TyG index values (all p < 0.001). A progressive worsening of lipid and metabolic parameters was observed across increasing METS-VF quartiles. Elevated TG/HDL-c ratio prevalence increased from 2.7% in the lowest METS-VF quartile to 15.8% in the highest quartile. Men showed a substantially higher prevalence of residual atherogenic dyslipidemia than women (12.2% vs. 3.9%, p < 0.001). Physical inactivity, smoking, poor Mediterranean diet adherence, and regular alcohol consumption were strongly associated with adverse lipid-metabolic profiles. In multivariable analyses using separate adiposity measures, BMI and METS-VF remained independently associated with elevated TG/HDL-c, whereas WtHR ≥ 0.50 was not independently associated after adjustment. Male sex, physical inactivity, smoking, impaired fasting glucose, elevated blood pressure, and low Mediterranean diet adherence showed consistent associations across models. Conclusions. Residual atherogenic dyslipidemia is highly prevalent among adults with normal BMI and is strongly associated with visceral adiposity, metabolic dysfunction, and unfavorable lifestyle-related behaviors. Conventional BMI classification alone substantially underestimates hidden cardiometabolic risk. These findings highlight the metabolic heterogeneity present among apparently healthy normal-weight individuals and the limitations of BMI as a sole marker of cardiometabolic health.
Related
- Combined statin probiotic treatment mitigates atherogenic dyslipidemia fueling NAFLD in high-cholesterol-diet fed rats
- D-allulose attenuates dyslipidemia, oxidative stress, and inflammation in high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in rats.
- Association of Visceral Adiposity, Core Skeletal Muscle Mass, Atherogenic Index of Plasma, and Renal Function (CKD-EPI) with Framingham Cardiovascular Risk Score in Adults: A Cross-Sectional Study
- Highly Esterified Starch Citrate Synthesized via Sequential Extrusion and Thermal Curing Attenuates Carbohydrate-Driven Adiposity and Dyslipidemia in Mice
- Metabolic, Atherogenic, and Anthropometric Markers for Discrimination of Premature Coronary Artery Disease in a Predominantly Statin-Treated Cohort.
BibTeX
@article{carrasco2026residual,
title = {{Residual Atherogenic Dyslipidemia in Normal-Weight Adults: The Role of Visceral Adiposity and Metabolic Dysfunction.}},
author = {Diego González Carrasco and Pedro Juan Tárraga López and Mónica Silu Piña Dabreu and Lluis Rodas Cañellas and Ángel Arturo López-González and José Ignacio Ramírez-Manent},
journal = {Medical sciences (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/medsci14060655},
url = {https://europepmc.org/article/MED/42930574},
note = {CC BY},
}
RIS
TY - JOUR
TI - Residual Atherogenic Dyslipidemia in Normal-Weight Adults: The Role of Visceral Adiposity and Metabolic Dysfunction.
AU - Diego González Carrasco
AU - Pedro Juan Tárraga López
AU - Mónica Silu Piña Dabreu
AU - Lluis Rodas Cañellas
AU - Ángel Arturo López-González
AU - José Ignacio Ramírez-Manent
PY - 2026
DA - 2026/10/09
JO - Medical sciences (Basel, Switzerland)
DO - 10.3390/medsci14060655
UR - https://europepmc.org/article/MED/42930574
AB - Background. Body mass index (BMI) remains the most widely used tool for obesity classification and cardiometabolic risk stratification. However, increasing evidence suggests that normal BMI does not necessarily reflect metabolic health, particularly in individuals with hidden visceral adiposity and residual atherogenic dyslipidemia. The present study aimed to evaluate the prevalence of residual atherogenic dyslipidemia among normal-weight adults and to analyze its association with visceral adiposity, metabolic dysfunction, and lifestyle-related factors. Methods. A cross-sectional observational study was conducted in 166,008 Spanish workers aged 18-69 years with normal BMI (18.5-24.9 kg/m²) who underwent standardized occupational health examinations between 2022 and 2024. Anthropometric, biochemical, vascular, and lifestyle-related variables were evaluated. Visceral adiposity was estimated using waist-to-height ratio (WtHR) and the Metabolic Score for Visceral Fat (METS-VF). Residual atherogenic dyslipidemia was primarily assessed using the triglyceride-to-HDL cholesterol ratio (TG/HDL-c). Multivariable logistic regression analyses were performed to identify independent associations with elevated TG/HDL-c. Results. Despite normal BMI values, 8.0% of participants presented with an elevated TG/HDL-c ratio, 11.8% had central adiposity, 11.4% showed low HDL cholesterol, and 17.9% exhibited elevated blood pressure. Individuals with an elevated TG/HDL-c ratio demonstrated significantly higher waist circumference, WtHR, METS-VF, triglycerides, non-HDL cholesterol, fasting glucose, blood pressure, and TyG index values (all p < 0.001). A progressive worsening of lipid and metabolic parameters was observed across increasing METS-VF quartiles. Elevated TG/HDL-c ratio prevalence increased from 2.7% in the lowest METS-VF quartile to 15.8% in the highest quartile. Men showed a substantially higher prevalence of residual atherogenic dyslipidemia than women (12.2% vs. 3.9%, p < 0.001). Physical inactivity, smoking, poor Mediterranean diet adherence, and regular alcohol consumption were strongly associated with adverse lipid-metabolic profiles. In multivariable analyses using separate adiposity measures, BMI and METS-VF remained independently associated with elevated TG/HDL-c, whereas WtHR ≥ 0.50 was not independently associated after adjustment. Male sex, physical inactivity, smoking, impaired fasting glucose, elevated blood pressure, and low Mediterranean diet adherence showed consistent associations across models. Conclusions. Residual atherogenic dyslipidemia is highly prevalent among adults with normal BMI and is strongly associated with visceral adiposity, metabolic dysfunction, and unfavorable lifestyle-related behaviors. Conventional BMI classification alone substantially underestimates hidden cardiometabolic risk. These findings highlight the metabolic heterogeneity present among apparently healthy normal-weight individuals and the limitations of BMI as a sole marker of cardiometabolic health.
SN - 2076-3271
ER -